Suxia Luo

2.1k total citations
26 papers, 514 citations indexed

About

Suxia Luo is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Suxia Luo has authored 26 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Suxia Luo's work include Circular RNAs in diseases (6 papers), Metastasis and carcinoma case studies (5 papers) and MicroRNA in disease regulation (5 papers). Suxia Luo is often cited by papers focused on Circular RNAs in diseases (6 papers), Metastasis and carcinoma case studies (5 papers) and MicroRNA in disease regulation (5 papers). Suxia Luo collaborates with scholars based in China, Singapore and Japan. Suxia Luo's co-authors include Xiaoli Liu, Qingfeng Jiang, Huaimin Liu, Zhenzhen Liu, Haiying Ma, Lei Cheng, Jia Li, Xianfu Sun, Miaomiao Sun and Yu Mu and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and European Journal of Pharmacology.

In The Last Decade

Suxia Luo

25 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suxia Luo China 12 357 242 86 70 41 26 514
Jingyu Zhang China 14 401 1.1× 205 0.8× 116 1.3× 65 0.9× 37 0.9× 41 611
Haoran Tang China 12 382 1.1× 169 0.7× 103 1.2× 53 0.8× 28 0.7× 29 577
Peiyan Hua China 15 367 1.0× 199 0.8× 87 1.0× 65 0.9× 39 1.0× 31 560
Zhongqiang Guo China 13 346 1.0× 150 0.6× 90 1.0× 98 1.4× 41 1.0× 24 539
Xuan Zhu China 15 339 0.9× 273 1.1× 91 1.1× 43 0.6× 31 0.8× 28 519
Renyi Qin China 11 380 1.1× 254 1.0× 103 1.2× 54 0.8× 25 0.6× 12 586
Xiali Tang China 10 370 1.0× 262 1.1× 97 1.1× 58 0.8× 31 0.8× 14 547
Aimin Zang China 11 248 0.7× 189 0.8× 116 1.3× 51 0.7× 29 0.7× 47 428

Countries citing papers authored by Suxia Luo

Since Specialization
Citations

This map shows the geographic impact of Suxia Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suxia Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suxia Luo more than expected).

Fields of papers citing papers by Suxia Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suxia Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suxia Luo. The network helps show where Suxia Luo may publish in the future.

Co-authorship network of co-authors of Suxia Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Suxia Luo. A scholar is included among the top collaborators of Suxia Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suxia Luo. Suxia Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Ning, Xiaohui Gao, Xuesong Zhao, et al.. (2024). First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study. Signal Transduction and Targeted Therapy. 9(1). 303–303. 2 indexed citations
3.
Shi, Yuankai, Xiaohong Han, Qian Zhao, et al.. (2024). Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study. Experimental Hematology and Oncology. 13(1). 60–60. 4 indexed citations
4.
Wang, Jing, Weicheng Lu, Yong Cheng, et al.. (2023). POU2F1/DNMT3a Pathway Participates in Neuropathic Pain by Hypermethylation-Mediated LRFN4 Downregulation Following Oxaliplatin Treatment. Neurochemical Research. 48(12). 3652–3664. 2 indexed citations
5.
6.
Ma, Fei, et al.. (2021). Various Kinds of Functional Digestive Tract Reconstruction Methods After Proximal Gastrectomy. Frontiers in Oncology. 11. 685717–685717. 14 indexed citations
7.
8.
Luo, Suxia, et al.. (2021). Novel lncRNA LINC00941 Promotes Proliferation and Invasion of Colon Cancer Through Activation of MYC. OncoTargets and Therapy. Volume 14. 1173–1186. 17 indexed citations
9.
10.
11.
Li, Juntao, et al.. (2020). Knockdown of LINC00665 inhibits proliferation and invasion of breast cancer via competitive binding of miR-3619-5p and inhibition of catenin beta 1. Cellular & Molecular Biology Letters. 25(1). 43–43. 18 indexed citations
12.
Li, Ning, et al.. (2020). Preliminary study on the relationship among stem cell markers, drug resistance and PI3K signaling pathway in multiple myeloma (MM) cell. Translational Cancer Research. 9(5). 3385–3391. 2 indexed citations
13.
14.
Sun, Xianfu, et al.. (2019). LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway. European Journal of Pharmacology. 856. 172407–172407. 68 indexed citations
15.
Li, Lianfang, et al.. (2019). Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR‐194‐5p. Journal of Cellular Physiology. 235(3). 2668–2675. 30 indexed citations
16.
Mu, Yu, et al.. (2017). FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. Biomedicine & Pharmacotherapy. 90. 548–554. 39 indexed citations
17.
Chen, Beibei, Xiaobing Chen, Liangyu Bie, et al.. (2015). Decreased expression of miR-542-3p exerts growth inhibitory functions in esophageal cancer. Journal of Cancer Research and Therapeutics. 11(Suppl 1). S24–S28. 16 indexed citations
18.
Cheng, Lei, et al.. (2013). FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell Death and Disease. 4(11). e923–e923. 97 indexed citations
19.
Luo, Suxia. (2012). Oxaliplatin induced neurotoxicity:mechanism and therapy. 1 indexed citations
20.
Chen, Xiaobing, Xinguang Cao, Wenjie Dong, et al.. (2009). Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation. Biochemical and Biophysical Research Communications. 391(1). 1070–1074. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jingyu Zhang Breakdown of academic impact, for papers by Haoran Tang Breakdown of academic impact, for papers by Peiyan Hua Breakdown of academic impact, for papers by Zhongqiang Guo Breakdown of academic impact, for papers by Xuan Zhu Breakdown of academic impact, for papers by Renyi Qin Breakdown of academic impact, for papers by Xiali Tang Breakdown of academic impact, for papers by Aimin Zang
Rankless by CCL
2026